Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that dMMR status confers therapeutic sensitivity to Ipilimumab, Nivolumab in patients with Colorectal Adenocarcinoma.

The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipilimumab as a treatment option for the first-line treatment of adult patient with unresectable or metastatic mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC).

This statement is based on a regulatory approval from the Health Service Executive:

Nivolumab in combination with ipilimumab for the first-line treatment of adult patient with unresectable or metastatic mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC).

Citation

Nivolumab 240 mg and Ipilimumab 1mg/kg Therapy, 2025, version number 1a, viewed 02/08/2026, https://healthservice.hse.ie/documents/6653/900_v1a_Nivolumab_240mg_ipilimumab_1mgkg_.pdf

Contributions

Date	Contributor	Description
2025-10-01	Health Service Executive	Indication approved for reimbursement.
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database